biotickrNeuroSense Therapeutics Ltd
The NRSN stock trades on Nasdaq All Markets
Company Description
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases. NeuroSense’s novel drug, PrimeC, aims to treat ALS by regulating microRNA synthesis, reducing neuroinflammation, and influencing iron accumulation.
Drug Pipeline
Source: NeuroSense Therapeutics Ltd - 20220916
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
PrimeC
Amyotrophic Lateral Sclerosis
Phase 2
StabiliC
Parkinson's Disease
Preclinical
Conversation
0 following
1 Comments on NRSN stock
Newest
In pre-clinical models of ALS, PrimeC showed outstanding results. These results were significantly superior to the outcome produced by other investigational or approved drugs when tested in these models. I think the company is well positioned financially to carry through the PrimeC Phase IIb study and intends to provide topline data in Q2 2023. Risk of dilution prior to this event is heavily mitigated.
Given both compounds which comprise PrimeC are already FDA approved and the existing trial data regarding safety, efficacy, and tolerability is positive this asset is heavily de-risked from a regulatory standpoint. Positive topline data from the Phase IIb study is critical at this juncture. If approved this treatment could become the standard of care for ALS patients.
This could be huge!